Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is scheduled to release its earnings data after the market closes on Tuesday, October 31st. Analysts expect Alnylam Pharmaceuticals to post earnings of ($1.26) per share for the quarter.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The firm’s quarterly revenue was up 82.9% on a year-over-year basis. During the same period in the previous year, the business posted ($1.05) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $-5.14 EPS for the current fiscal year and $-5.66 EPS for the next fiscal year.

Alnylam Pharmaceuticals, Inc. (ALNY) opened at 117.735 on Tuesday. The firm’s market cap is $10.80 billion. Alnylam Pharmaceuticals, Inc. has a 1-year low of $31.38 and a 1-year high of $126.16. The firm’s 50-day moving average is $105.95 and its 200 day moving average is $80.68.

In related news, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction that occurred on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total value of $10,664,500.00. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.

Several research analysts recently issued reports on ALNY shares. Needham & Company LLC upped their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the stock a “buy” rating in a research report on Tuesday, June 27th. Chardan Capital reissued a “buy” rating and set a $131.00 price objective (up from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. BidaskClub cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 29th. Ladenburg Thalmann Financial Services set a $90.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, July 17th. Finally, Zacks Investment Research raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 price objective for the company in a report on Wednesday, July 12th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. Alnylam Pharmaceuticals has an average rating of “Hold” and an average target price of $100.80.

WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) to Release Earnings on Tuesday” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/24/alnylam-pharmaceuticals-inc-alny-to-release-earnings-on-tuesday.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.